13550_2016_163_MOESM4_ESM.pdf (69.84 kB)
Additional file 4: Figure S4. of Targeted scVEGF/177Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy
journal contribution
posted on 2016-01-16, 05:00 authored by Mary Rusckowski, Yuzhen Wang, Francis Blankenberg, Zoia Levashova, Marina Backer, Joseph BackerRapid declining in VEGFR-2 prevalence in response to scVEGF/177 Lu treatment. The difference relative to control was statistically significant (p=0.0001) from Day 1. No statistically significant difference between VEGFR-2 prevalence at days 3 to 15 after treatment. The number of analyzed microscopic fields (N) on cryosections from different mouse tumors (n) for each time point was as following: N/n: Control – 19/4, D1 – 28/6, D3 – 24/5, D5 – 25/6, D8 – 32/6, D11 – 27/6, D15 – 27/6. (PDF 69 kb)